Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ADHD
Biotech
Alkermes eyes orexin ADHD drug as potential ‘company changer’
Alkermes is vying to be the first to push orexin agonists beyond sleep disorders and into broader patient populations like ADHD and fatigue.
Darren Incorvaia
Sep 21, 2026 7:00am
Otsuka posts phase 3b ADHD trial win ahead of looming FDA ruling
Jun 25, 2026 9:13am
FDA clears Lumosity brain training games for adult ADHD
Dec 11, 2025 10:00am
Akili cuts workforce another 40%, eyes OTC digital app model
Sep 14, 2023 10:35am
Akili's video game ADHD treatment now available for adults
Jun 7, 2023 3:05pm
Akili aims to expand its videogame ADHD treatment to adults
May 3, 2023 1:00pm
